Publications

Add filters (0)

157 results

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

Sustained Improvement of Cognition, Mood and Plasma Markers Three Years After Metabolic Bariatric Surgery. The BARICO Study.

September 1, 2025

Obes Surg

Abstract BACKGROUND The primary aim of this study is to investigate the impact of MBS induced weight loss on cognition, and secondary investigate the impact of this weight loss on adipokines, inflammatory factors, vascular markers, mood and physical activity three years after MBS. METHODS This observational study assessed data from 107 patients with severe obesity […]

Read publication

Divergent Changes in Peak Fat Oxidation and Fat(max) Following 3-Day Dietary Interventions Are Related to Muscle Glycogen Availability in Men.

September 1, 2025

Scand J Med Sci Sports

Abstract Dietary intake has an important influence on rates of fuel use during exercise, but the extent to which short-term diet changes affect peak fat oxidation (PFO) and the intensity at which this occurs (Fat) is unknown. This study examined the impact of diet-induced changes in substrate availability on PFO and Fat and the expression […]

Read publication

Serological assessment of PRO-C16 (type XVI collagen formation) reflects intestinal fibrostenotic strictures in patients with crohn’s disease.

August 8, 2025

BMC Gastroenterol

Abstract BACKGROUND Fibrostenotic stricturing disease affects 30-50% of patients with Crohn’s disease (CD), leading to intestinal resection. Currently, there exists a great medical need to identify biomarkers related to fibrostenotic strictures for optimized patient management. Thus, we investigated PRO-C16 as a biomarker for intestinal fibrosis in patients with CD. METHODS Human serum from two independent […]

Read publication

Fibroblast activities are associated with prolonged QTc and pulmonary arterial hypertension in patients with systemic sclerosis.

August 1, 2025

Clin Exp Rheumatol

Abstract OBJECTIVES In systemic sclerosis patients (SSc), we aimed at exploring the potential of serum biomarkers of fibrosis and immune-cell activity to detect subclinical heart involvement determined by electrocardiographic (ECG) alterations. METHODS A panel of extracellular matrix (ECM) turnover biomarkers quantifying type III and VI collagen formation (PRO-C3 and PRO-C6), type IV collagen turnover (PRO-C4), […]

Read publication

Serum biochemical marker of synovial tissue turnover, C1M, predicts radiological progression in early rheumatoid arthritis.

July 10, 2025

RMD Open

Abstract OBJECTIVES To investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis. METHODS 813 early arthritis patients (<6 months of symptoms, 82% with rheumatoid arthritis, 18% undifferentiated arthritis) from the prospective ESPOIR study were followed for 5 years. […]

Read publication